Preliminary study of 18F-FAPI PET/CT in hypertrophic cardiomyopathy: comparison with cardiac magnetic resonance imaging

doi:10.3969/j.issn.1006-7795.2022.06.005

Abstract

Abstract: Objective To explore the characteristics of ¹⁸F-labeled fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography (PET/CT) in the patients with hypertrophic cardiomyopathy (HCM), as well as the correlation between ¹⁸F-FAPI activity and cardiac magnetic resonance (CMR) late gadolinium enhancement (LGE) technique. Methods Twenty-two HCM patients were prospectively recruited in this study with ¹⁸F-FAPI PET/CT examination, CMR examination and blood tests. A control group of twenty-two healthy participants with the same age and sex as the HCM group was also recruited and only underwent ¹⁸F-FAPI PET/CT examination. The maximum standardized uptake value (SUV_max) and maximum target-to-background ratio (TBR_max) of left ventricular (LV) myocardium were then obtained by post-processing software. The region grow algorithm with a threshold of 40% of the SUV_max was set to determine the ¹⁸F-FAPI volume. The ¹⁸F-FAPI volume was further expressed as a percentage of LV volume derived from CMR, which was defined as the ¹⁸F-FAPI extent (FAPI%). CMR examination was performed on a 3.0 Tesla scanner. The maximum thickness and LGE extent (LGE%) of LV myocardium were then obtained by post-processing software. The independent-sample t test or Mann Whitney U test was used to evaluate the differences of ¹⁸F-FAPI uptake between the patients with HCM and healthy participants. The correlation of ¹⁸F-FAPI activity and CMR parameters were assessed by Pearson/Spearman's correlation test. Results The myocardial ¹⁸F-FAPI uptake of LV in patients with HCM was significantly higher than that in the healthy participants (TBR_max, median: 8.96 vs 1.19, P<0.001). In patients with HCM, the ¹⁸F-FAPI extent was larger than LGE extent (FAPI% vs LGE%, median: 73.77 vs 6.69, P<0.001), and moderate correlation was observed between ¹⁸F-FAPI extent, LGE extent and LVEF (FAPI, LGE% and LVEF, r = 0.67,-0.49, P<0.05).Moreover, moderate correlation was observed between ¹⁸F-FAPI extent with N-terminal pro-B-type natriuretic peptide (NT-proBNP) and creatine kinase-MB (CK-MB) (FAPI% , NT-proBNP and CK-MB, r = 0.58,0.54, P<0.05). No correlation was observed between CMR parameters and blood tests. Conclusion The measurement of ¹⁸F-FAPI was moderately correlated with the CMR, and ¹⁸F-FAPI PET/CT could detect a wider range of myocardium than CMR.

Key words: fibroblast activation protein inhibitor, cardiac magnetic resonance, hypertrophic cardiomyopathy

CLC Number:

Zhang Yu, Dong Zhixiang, Li Changcheng, Wang Li, Yang Minfu. Preliminary study of ¹⁸F-FAPI PET/CT in hypertrophic cardiomyopathy: comparison with cardiac magnetic resonance imaging[J]. Journal of Capital Medical University, 2022, 43(6): 845-853.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2022.06.005

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2022/V43/I6/845

References

[1] Bittencourt M I, Cader S A, Araújo D V, et al. Role of myocardial fibrosis in hypertrophic cardiomyopathy: a systematic review and updated Meta-Analysis of risk markers for sudden death[J]. Arq Bras Cardiol, 2019, 112(3): 281－289.
[2] Maron B J, Maron M S, Rowin E J. Perspectives on the overall risks of living with hypertrophic cardiomyopathy[J]. Circulation, 2017, 135(24): 2317－2319.
[3] Sara L. Myocardial fibrosis in hypertrophic cardiomyopathy: what remains to be proven?[J]. Arq Bras Cardiol, 2019, 112(3): 290－291.
[4] Xie B Q, Wang J X, Xi X Y, et al. Fibroblast activation protein imaging in reperfused ST-elevation myocardial infarction: comparison with cardiac magnetic resonance imaging[J]. Eur J Nucl Med Mol Imaging, 2022, 49(8): 2786－2797.
[5] Chen B X, Xing H Q, Gong J N, et al. Imaging of cardiac fibroblast activation in patients with chronic thromboembolic pulmonary hypertension[J]. Eur J Nucl Med Mol Imaging, 2022, 49(4): 1211－1222.
[6] Ommen S R, Mital S, Burke M A, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. J Am Coll Cardiol, 2020, 76(25): 3022－3055.
[7] Wang S L, Zhou X, Xu X X, et al. Clinical translational evaluation of Al¹⁸F-NOTA-FAPI for fibroblast activation protein-targeted tumour imaging[J]. Eur J Nucl Med Mol Imaging, 2021, 48(13): 4259－4271.
[8] Wang L, Wang Y L, Wang J, et al. Myocardial activity at ¹⁸F-FAPI PET/CT and risk for sudden cardiac death in hypertrophic cardiomyopathy[J/OL]. Radiology. (2022－10－11)[2022-10-20].https://pubmed.ncbi.nlm.nih.gov/36219116/.
[9] Kurose H. Cardiac fibrosis and fibroblasts[J]. Cells, 2021, 10(7): 1716.
[10] McDowell K S, Arevalo H J, Maleckar M M, et al. Susceptibility to arrhythmia in the infarcted heart depends on myofibroblast density[J]. Biophys J, 2011, 101(6): 1307－1315.
[11] Chaldoupi S M, Loh P, Hauer R N W, et al. The role of connexin40 in atrial fibrillation[J]. Cardiovasc Res, 2009, 84(1): 15－23.
[12] Ambale-Venkatesh B, Lima J A C. Cardiac MRI: a central prognostic tool in myocardial fibrosis[J]. Nat Rev Cardiol, 2015, 12(1): 18－29.
[13] Quarta G, Aquaro G D, Pedrotti P, et al. Cardiovascular magnetic resonance imaging in hypertrophic cardiomyopathy: the importance of clinical context[J]. Eur Heart J Cardiovasc Imaging, 2018, 19(6): 601－610.
[14] 中华医学会心血管病学分会中国成人肥厚型心肌病诊断与治疗指南编写组, 中华心血管病杂志编辑委员会. 中国成人肥厚型心肌病诊断与治疗指南[J]. 中华心血管病杂志, 2017, 45(12): 1015－1032.
[15] Moravsky G, Ofek E, Rakowski H, et al. Myocardial fibrosis in hypertrophic cardiomyopathy: accurate reflection of histopathological findings by CMR[J]. JACC Cardiovasc Imaging, 2013, 6(5): 587－596.
[16] Freitas P, Ferreira A M, Arteaga-Fernández E, et al. The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of patients with hypertrophic cardiomyopathy at risk of sudden cardiac death[J]. J Cardiovasc Magn Reson, 2019, 21(1): 50.
[17] Liu J, Zhao S H, Yu S Q, et al. Patterns of replacement fibrosis in hypertrophic cardiomyopathy[J]. Radiology, 2022, 302(2): 298－306.
[18] Nakagawa Y, Nishikimi T, Kuwahara K. Atrial and brain natriuretic peptides: hormones secreted from the heart[J]. Peptides, 2019, 111: 18－25.
[19] Rørth R, Jhund P S, Yilmaz M B, et al. Comparison of BNP and NT-proBNP in patients with heart failure and reduced ejection fraction[J]. Circ Heart Fail, 2020, 13(2): e006541.
[20] Hamada M, Shigematsu Y, Ohtani T, et al. Elevated cardiac enzymes in hypertrophic cardiomyopathy patients with heart failure-a 20-year prospective follow-up study[J]. Circ J, 2016, 80(1): 218－226.

Preliminary study of ¹⁸F-FAPI PET/CT in hypertrophic cardiomyopathy: comparison with cardiac magnetic resonance imaging

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 1

Recommended Articles

Metrics

Comments